A Post-market Observational ORIGIN® CR Clinical Study

Sponsor
Symbios Orthopedie SA (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05607966
Collaborator
(none)
199
55

Study Details

Study Description

Brief Summary

The study objective is to evaluate safety and performance of the ORIGIN® CR (cruciate retaining) devices and associated instruments, more precisely to evaluate safety by the proportion of patients requiring a revision (i.e. revision rate) at 1-year post procedure and to evaluate performance by means of a Knee Society Score (KSS) Knee Score at 1 year post procedure and by means of a KSS Function Score also at 1 year post procedure.

The hypothesis raised for this study, regarding the scoring, is that patients will experience a marked improvement in the natural feel of the prosthesis during the first year after the surgery, and slightly significant improvement at the following interval of 2 years. The overall patient satisfaction is expected to be improved after 2 years follow-up with ORIGIN® CR.

Condition or Disease Intervention/Treatment Phase
  • Device: ORIGIN® CR devices

Detailed Description

The study is a prospective, non-comparative, non-randomized, single-arm, observational, post market study in which 199 patients will be enrolled to evaluate the safety and performance of the ORIGIN® CR devices and associated instruments.

Patients will be included in the study during 18 months (inclusion window) and followed-up for 24 months.

Study Design

Study Type:
Observational
Anticipated Enrollment :
199 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Post-market Observational ORIGIN® CR Clinical Study
Anticipated Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
Mar 1, 2027
Anticipated Study Completion Date :
Jun 1, 2027

Outcome Measures

Primary Outcome Measures

  1. Evaluate safety by the proportion of required revisions [1 year post-procedure]

    Proportion of patients requiring a revision after 1-year post-procedure. The revision rate is consistent with the state of the art - Orthopaedic Data Evaluation Panel (ODEP) benchmark system (revision rate not higher than 2.5% to 3.5% at 1 year, 4% to 6% at 5 years and 5% to 7% at 10 years).

  2. Evaluate performance [1 year post-procedure]

    Evaluate performance by means of following questionnaires: Knee Society Score (KSS) and a Knee Society Function score, a partient-reported outcome measure. The KSS contains questions in 2 sections: knee joint (pain, range of motion, stability) and function (walking distance, ability to climb stairs). When calculating the score, deductions are taken for assistive devices and flexion contractures, misalignment, or extension lag. The maximum points which can be reached are 100 points. Clinical status assessed by means of the KSS Knee score at 1 year post procedure Clinical status assessed by means of the KSS Function score at 1 year post procedure

Secondary Outcome Measures

  1. Evaluate safety by the proportion of required revisions [2 years post procedure]

    Proportion of patients requiring a revision after 2 years post-procedure.

  2. Performance on patient satisfaction [1- and 2-years post-procedure]

    Patient satisfaction questionnaires at 1 year and 2 years follow-up visits.

  3. Quality of Life post-procedure measured by the Knee Society score and Knee Society function questionnaire [1- and 2-years post-procedure]

    Quality of Life measured by means of the Knee Society score and Knee Society function score questionnaires at 1- and 2-years follow-up visit.

  4. Quality of Life post-procedure measured by the Forgotten Joint Score questionnaire [1- and 2- years post-procedure]

    Quality of Life measured by means of the Forgotten Joint Score questionnaire at 1- and 2-years follow-up visit. 12 questions refer to how aware the patients are of their artificial hip/knee joint in everyday life Scoring: For scoring the FJS-12, all responses are summed (never, 0 points; almost never, 1 point; seldom, 2 points; sometimes, 3 points; mostly, 4 points) and then divided by the number of completed items. This mean value is subsequently multiplied by 25 to obtain a total score range of 0 to 100. Finally, the score is subtracted from 100, to change the direction of the final score in a way that high scores indicate a high degree of "forgetting" the artificial joint, that is, a low degree of awareness. If more than 4 responses are missing, the total score should not be used.

  5. Quality of Life post-procedure measured by the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score questionnaire [1- and 2- years post-procedure]

    Quality of Life measured by means of the Western Ontario and McMaster Universities Arthritis Index (WOMAC) questionnaire at 1- and 2-years follow-up visit. It is a self-administered questionnaire consisting of 24 items divided into 3 subscales: Pain (5 items): during walking, using stairs, in bed, sitting or lying, and standing upright Stiffness (2 items): after first waking and later in the day Physical Function (17 items): using stairs, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy domestic duties, light domestic duties. The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Usually, a sum of the scores for all three subscales gives a total WOMAC score, which is 96 points.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male and female over 18 years of age

  • Each patient who is willing to give informed consent.

  • Clinically indicated for a total knee replacement

  • Females who are not pregnant and not planning to become pregnant ≤ 12 months. A pregnancy test should be performed for women of childbearing age

  • Geographically stable and willing to return to the implanting site for all follow-up visits at 1 year and 2 years.

Exclusion Criteria:
  • Life expectancy ≤ 1 year

  • Acute or chronic, local or systemic infection

  • Mental illness

  • Muscular, ligamental, neurological, psychological or vascular deficits

  • Bone destruction or poor bone quality likely to affect implant stability (requiring a femoral and/or a tibial stem and/or a thick insert)

  • Any concomitant condition likely to affect implant integration or function

  • Allergy or hypersensitivity to any of the materials used

  • For devices in CoCrMo (ISO 5832/4): renal and hepatic impairment

  • Hip Knee Ankle (HKA) angle < 165° or > 195°

  • Severe collateral ligaments deficiency (requiring a more constrained prosthesis)

  • Posterior cruciate ligament deficiency

  • Major anatomical deformities

  • Severe flexion contracture or severe recurvatum

  • Revision of a partial or total knee prosthesis

  • Non-extractible material (e.g. screws, plate, intramedullary nail, osteosynthesis material…) which can create a conflict with any component of the prosthesis

  • Distal and/or posterior and/or anterior femoral bone loss which exceeds the femoral component thickness

  • Proximal tibial bone loss which exceeds the tibial component thickness (tibial tray + tibial insert)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Symbios Orthopedie SA

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Symbios Orthopedie SA
ClinicalTrials.gov Identifier:
NCT05607966
Other Study ID Numbers:
  • CLIN-G-014
First Posted:
Nov 7, 2022
Last Update Posted:
Nov 7, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Symbios Orthopedie SA

Study Results

No Results Posted as of Nov 7, 2022